Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Clinical trials sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd., explained in plain language.
-
New pill targets stubborn sinus infections
Disease control Recruiting nowThis study is testing an oral tablet called HTMC0658 to see if it can help control chronic sinus inflammation in people who do not have nasal polyps. It will enroll 30 adults who have had sinus symptoms for over 12 weeks despite using a standard nasal spray. Researchers will meas…
Phase: PHASE2 • Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Race to free sepsis patients from ventilators
Disease control Recruiting nowThis study is testing whether a new drug called YD0743 can help adults in the ICU with sepsis-related acute respiratory distress syndrome (ARDS). Researchers want to see if the drug can reduce the number of days patients need a breathing machine and improve their chances of survi…
Phase: PHASE2 • Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New pain pill tested for surgery recovery
Symptom relief Recruiting nowThis study is testing an experimental tablet called HL-1186 to see if it safely reduces moderate to severe pain after surgery. It will involve 72 adults who have just had orthopedic, abdominal, or chest surgery. Researchers will compare the new pill to a placebo (a dummy pill) to…
Phase: PHASE2 • Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. • Aim: Symptom relief
Last updated Mar 23, 2026 15:17 UTC
-
New pill tested to ease Post-Surgery pain
Symptom relief Recruiting nowThis study is testing whether a new tablet called HL-1186 can safely and effectively reduce pain after abdominal surgery. It will compare the pill to a placebo (a dummy pill) in about 40 adults. The main goal is to see if the new pill provides better pain relief over the first 48…
Phase: PHASE2 • Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. • Aim: Symptom relief
Last updated Mar 20, 2026 14:47 UTC